Skip to content

EXTRA-PHARMA

Active Private limited companyfounded 1999active for 27 yearsAntwerpsesteenweg 188, 2950 KapellenKBO/BCE: BE 0467.149.426 subsidiary of Cavely
EXTRA-PHARMA
Follow ReportCompare

Overview

Lifetime

19 annual accounts with figures on one time axis, 25 filings since 2001
peak €896,503 (2024)
€765,107▼ 14.7%
peak €413,070 (2024)
€97,780▼ 76.3%
peak €3.3m (2023)
€559,094▲ 17.2%
€2.5m▼ 15.2%
peak 9.2 FTE (2024)
8.7 FTE▼ 5.4%
Board4 names since 2020
1 directorCavely
Owners2 names in the annual accounts
100%Cavely
Documentsfilings and deeds
29-09-202532 days before the deadline
2025abbreviated format
Gross margin from €896,503 to €765,107Result from €413,070 to €97,780Equity from €477,161 to €559,094Debts from €3.0m to €2.5mCash from €446,044 to €159,799

Key points

from the 2025 annual accounts

Equity

€559,094 from €3.3m in 2023

Equity fell by 83% in 2 years.

Result

€97,780 ▼ 76.3%
€413,0002024€97,8002025

The result fell in 2025 from €413,070 to €97,780.

Debts

€2.5m 82% of the balance sheet
Financial debts 74%Suppliers 15%Taxes and wages 2%Other 9%

€1.9m of the debts are secured on the company's own assets. In 2022 that was €750,000.

Securities

€2.1m

Mortgage mandates, new in 2025. 3.8 times equity · not in the 2024 accounts.

Staff

12 employees on 31-03-2025
732022362023432024342025

In 2025, 3 people joined and 4 left.

Filings

25 annual accounts 9 days past the deadline
deadline20102020

2026 accounts not filed: deadline was 31-10-2026.

Checked score

55
Fair
Financially stronger than 49% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.3% 01-2025: 0.3%● unchanged vs 12-2024lowest value 02-2025: 0.3%● unchanged vs 01-2025lowest value 03-2025: 0.3%● unchanged vs 02-2025lowest value 04-2025: 0.3%● unchanged vs 03-2025lowest value 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.4%▲ +0.1 percentage points vs 05-2025 07-2025: 0.4%● unchanged vs 06-2025 08-2025: 0.5%▲ +0.1 percentage points vs 07-2025 09-2025: 0.5%● unchanged vs 08-2025 10-2025: 0.6%▲ +0.1 percentage points vs 09-2025 11-2025: 0.6%● unchanged vs 10-2025 12-2025: 0.6%● unchanged vs 11-2025 01-2026: 0.6%● unchanged vs 12-2025 02-2026: 0.6%● unchanged vs 01-2026 03-2026: 0.6%● unchanged vs 02-2026 04-2026: 0.6%● unchanged vs 03-2026 05-2026: 0.6%● unchanged vs 04-2026 06-2026: 0.7%▲ +0.1 percentage points vs 05-2026 07-2026: 0.7%● unchanged vs 06-2026 08-2026: 0.8%▲ +0.1 percentage points vs 07-2026 09-2026: 0.8%● unchanged vs 08-2026 10-2026: 1.5%▲ +0.7 percentage points vs 09-2026 11-2026: 1.7%▲ +0.2 percentage points vs 10-2026highest value

Financial strength
Average

43+4equity 18.2% of total assets
49-5short-term debt 21.9% · cash 5.2%
60+7return on assets 3.2%

Score breakdown

raises risk
Figures for financial year 2025 (filed on 07-10-2025)
Size: 8.7 FTE, total assets €3.1m
Equity €559,094 (18.2% of total assets)
Sector: Retail trade (NACE 47)
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 34% of them on solvency, 49% on liquidity, 42% on profitability and 70% on growth.

The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-03-2025.

Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 3,984 companies had the same profile as EXTRA-PHARMA has now. Each dot stands for 10 companies, two years later.

96.5%
were still trading
2.3%
stopped another way
1.1%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet

Another 0.1% stopped without a precise date, possibly only after those two years.

The bankruptcy probability of EXTRA-PHARMA itself is higher: 1.7% within 12 months. It rests on far more data about EXTRA-PHARMA than the profile alone.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,984 companies, not a prediction for EXTRA-PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €30,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 1.98 (1.63 in 2024), above the usual 1.5. Short-term debt is 21.9% and cash 5.2% of total assets. However, 81.8% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
raises riskneutral
raises risk · Figures for financial year 2025 (filed on 07-10-2025)
NBB · annual accounts
raises risk · Size: 8.7 FTE, total assets €3.1m
Companies of this size fail more often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Equity €559,094 (18.2% of total assets)
NBB · annual accounts
raises risk · Sector: Retail trade (NACE 47)
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 29-09-2025, 32 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
not filed
2025
32 days early
2024
2 days early
2023
on the day
2022
3 days early
2021
15 days late
2020
17 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 6 accounts on average 1 day before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.

Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

C
Cavely
Director, Carlijn VAN DEN EEDE
  • Cavely 100%score 92equity €301,713 (2025) · 30-06-2025 annual accounts of Cavely
  • VERLUCO 98%equity €5.2m (2024) · 30-06-2023 annual accounts of VERLUCO
Board & ownership

Recent changes

1 director appointed, 2 resignations Resignations: Véronique VAN ROEY and VERLUCO NV · Permanent representatives: Luc VAN DEN EEDE and Carlijn VAN DEN EEDE · Appointment: CAVELY BV · General meeting of 02-04-2024 · Gazette deed
Environmental permit granted Nieuwbouw of aanleggen, Nieuwbouw van bijgebouwen, niet-overdekte lage constructies en andere handelingen, Verbouwen en/of uitbreiden met het wijzigen van alle zelfstandige gebruikseenheden (unit) binnen het gebouw and 2 more · Kapellen
1 manager resigning Changes of role: VAN ROEY Véronique (director) and VERLUCO (director) · Resignation: VAN DEN EEDE Luc Roger Johan Theo (manager) · “Het verlenen van advies en prestaties aan apotheken,verenigingen,bedrijven,de overheid,universiteiten en…” (deed in Dutch) · Gazette deed
First establishment Antwerpsesteenweg 188, Kapellen
All 34 events

Comparable companies

same main activity, similar in size and age
Company
EXTRA-PHARMA Kapellen €3.1m €0.8m 18.2% 8.7
PHARMACIE HENRY Pont-à-Celles €2.9m €0.9m 47.2% 8.1
PHARMA & FLO Namur €2.6m €0.7m 57.9% 7.6
APO2370 Arendonk €3.9m €1.0m 25.4% 7.9
E-pharma Antwerp €3.1m €0.8m 15.9% 8.8
PHARMACIE TILMAN Durbuy €2.5m €0.8m 15.5% 7.3
PHARMAYOU WANZE Wanze €3.1m €1.0m 46.4% 7

These companies have the same main activity as EXTRA-PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €2.5m and €3.9m, founded between 1996 and 2009.

Official details

Source: KBO
Status
Active since 26-10-1999Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 31-03-2025
Establishment unit
2.097.435.3542950 Kapellen, since 10-07-2000
Financial year end
31 March
Peppol
Reachable
Company details

Annual accounts to 31-03-2025

€765,107▼ 14.7%
≈ €2.7mestimated
€97,780▼ 76.3%
€559,094▲ 17.2%
€3.1m▼ 10.7%
Employeeson 31-03-2025
12▼ 7.7%
Filing
Filed on 29-09-2025
Financials

Companies linked to EXTRA-PHARMA

Insights on EXTRA-PHARMA

EXTRA-PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €475,725 in 2007 to €765,107 in 2025.

The balance sheet grew most from 2021 to 2023 through fixed assets.

Cavely holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 29-09-2025, 32 days before the deadline
€765,107
▼ 14.7%
€132,516
▼ 46.8%
€97,780
▼ 76.3%
€657,231
▲ 5.0%
18.2%
▲ 4.3 percentage points
1.98
▲ 0.35

Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €2.7m. Estimated: probably between €2.1m and €4.3m.

Balance sheet

balance sheet total €3.1m on 31-03-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

18.2%

Higher than 29% of 12,853 companies in 2025.

1.98

Higher than 62% of 12,643 companies in 2025.

3.2%

Higher than 44% of 12,717 companies in 2025.

EXTRA-PHARMA Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: top quarter · Equity: middle half · Balance sheet total: top quarter · Working capital: top quarter · Staff: top quarter

Staff

€60,319

Staff costs divided by the average number of full-time equivalents.

-1 person

people who joined people who left

In 2025, 3 people joined and 4 left.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420232022202120202019201820172016201520142013201220112010200920082007
Balance sheet: assets
20/58 3.1m3.4m6.2m5.0m4.4m3.6m3.5m3.2m3.1m2.7m2.8m2.7m2.6m2.5m2.3m2.2m2.2m2.2m2.0m
21/28 1.7m1.8m2.3m1.2m889,94247,51223,72035,50952,21574,59097,240128,667174,456191,066217,582292,645365,636449,275539,726
21 ----------------15,90643,17570,443
22/27 1.7m1.8m2.3m1.2m889,94247,51223,72035,50952,21574,59097,240128,667174,456191,066217,582292,645349,730406,100469,283
22 1.6m1.7m2.2m1.1m805,9613,52511,33624,10636,87649,64665,17280,69896,223111,749127,275166,162183,267200,373217,478
23 137,480146,938186,44577,91283,98243,98812,38411,40315,33921,65122,01431,15354,65564,42088,772124,436166,462205,728250,148
24 --------03,29310,05516,81623,57814,8971,5352,046--1,658
29/58 1.3m1.6m3.9m3.9m3.5m3.5m3.4m3.2m3.0m2.7m2.7m2.6m2.4m2.3m2.0m1.9m1.8m1.8m1.5m
3 518,787524,082492,614418,883439,807413,874399,798422,024407,848350,471350,875302,915302,964267,406259,554287,753288,020295,159290,405
30/36 518,787524,082492,614418,883439,807413,874399,798422,024407,848350,471350,875302,915302,964267,406259,554287,753288,020295,159290,405
40/41 274,774248,147493,042407,297387,569420,512775,354703,228732,8961.2m1.2m1.1m1.2m1.1m923,334905,994703,030556,665456,155
40 215,503205,143191,588184,594147,909220,591236,618201,531236,319198,516223,973173,949247,455200,591182,094183,187183,689168,243153,203
41 59,27143,004301,454222,704239,659199,921538,737501,697496,578996,5101.0m969,771981,855853,569741,240722,807519,340388,422302,952
50/53 372,754403,1822.7m2.7m2.3m2.5m1.7m1.7m1.6m840,565829,491814,986649,966502,312250,785250,785250,785250,785-
54/58 159,799446,044171,804304,759349,125260,119536,829352,215262,842275,967252,065303,082241,901434,010585,332463,302527,966635,300709,991
490/1 1,9807593195,743396--7,8367,1699,4866,26927,36819,67821,52922,91120,82424,08918,12418,963
Balance sheet: equity and liabilities
10/49 3.1m3.4m6.2m5.0m4.4m3.6m3.5m3.2m3.1m2.7m2.8m2.7m2.6m2.5m2.3m2.2m2.2m2.2m2.0m
10/15 559,094477,1613.3m3.2m2.9m2.9m2.6m2.5m2.3m2.0m1.8m1.5m1.3m1.1m884,083731,604620,832488,138402,956
10/11 18,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,600
100 -----18,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,60018,600
13 70,90270,902287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038287,038
130/1 ---1,8601,860--------------
130 -----1,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,8601,860
1311 ---1,8601,860--------------
133 70,90270,902287,038285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178285,178
14 469,592387,6593.0m2.9m2.6m2.5m2.3m2.2m2.0m1.7m1.5m1.2m1.0m775,545578,445425,966315,194182,50097,317
17/49 2.5m3.0m2.9m1.9m1.4m744,495811,652761,000802,901735,760991,4301.2m1.3m1.4m1.4m1.5m1.5m1.7m1.6m
17 1.8m2.0m2.1m1.0m693,750--10,33325,83341,33260,20795,998153,426210,854270,709348,981439,683551,698604,586
170/4 1.8m2.0m2.1m1.0m693,750--10,33325,83341,33260,20795,998131,997167,996206,423263,267332,540401,698454,586
175 ------------21,42942,85864,28685,715107,143150,000150,000
42/48 670,862996,053823,274835,337732,560741,895809,052750,666777,069694,428931,2231.1m1.1m1.2m1.1m1.1m1.1m1.2m1.0m
42 194,293265,808251,20657,10037,500-9,81416,79115,49918,87535,99957,63757,42859,85678,27290,49490,33168,73365,747
43 32,42632,22231,66832,32032,37532,22236,66736,88236,89436,91427,74534,71326,05717,71717,50035,00020,34523,33344,178
430/8 32,42632,22231,66832,32032,37532,22236,66736,88236,89436,91427,74534,71326,05717,71717,50035,00020,34523,33344,178
44 368,072366,848461,401684,473604,269652,557726,887653,961674,670596,362827,835928,5051.0m1.0m974,712979,518967,870944,954875,926
440/4 368,072366,848461,401684,473604,269652,557726,887653,961674,670596,362827,835928,5051.0m1.0m974,712979,518967,870944,954875,926
45 60,17755,71755,63443,46840,49739,23535,68543,03250,00642,27839,64461,69929,80356,09934,22235,70620,46628,45121,848
450/3 131,168-----7,72615,77813,5303,9854,0514,81328,9374,3233064695,182291
454/9 60,16454,54955,63443,46840,49739,23535,68535,30634,22828,74835,65957,64824,99027,16229,89935,40019,99723,26921,556
47/48 15,895275,45823,36517,97717,91817,882-----------100,000-
492/3 3,6974,3364,0773,4133,3622,6002,600------------
Income statement
76A 2,069---2,1502883,5004,714-1,7437301,205-2439,5261,86269512,4582,598
9900 765,107896,503785,271796,528645,323676,187615,694656,818716,499689,022690,032715,010694,914698,865610,749598,611574,504543,833475,725
62 524,774529,424488,546387,063352,492365,663356,276327,665322,163304,390303,464352,258310,810342,611324,881325,400268,665213,651206,769
630 104,535102,91580,68283,46070,10920,02218,23217,32227,45536,56252,57246,45047,63444,55053,52982,953100,243100,061100,895
640/8 3,2825,6704,9754,1628,4993,2802,9514,5043,6533,5813,2593,2357,3063,9143,1813,1852,7562,7242,710
66A -9,190------57---619------
9901 132,516249,304211,067321,843214,224287,223238,236307,328363,228344,489330,736313,068329,165307,790229,158187,074202,840227,396165,351
75/76B 54,678372,39419,88240,75142,39338,69714,55624,7978,39220,53415,34118,90326,9473,8601,8902,13914,92110,8657,613
75 52,488370,30817,22238,83740,24338,40911,05620,0838,39220,53415,34118,90326,9473,8601,8902,13914,92110,8657,613
76B 2,1912,0872,6601,9142,1502883,5004,714-----------
65/66B 53,176155,78144,67427,87292,2809,9584,8787,0199,22613,94614,11612,89615,34616,66919,91423,64626,10027,08731,012
65 53,176155,78144,67427,87292,2809,9584,8787,0199,16813,94614,11612,89615,34616,66919,91423,64626,10027,08731,012
66B --------57----------
9903 134,019465,917186,275334,721164,336315,961247,915325,106362,394352,821332,692320,280340,147295,223220,660167,429192,356223,633144,549
67/77 36,23952,8485,82981,94150,65594,10474,682107,726115,763113,311104,04399,084100,33898,12368,18156,65759,66238,45047,232
9904 97,780413,070180,445252,780113,682221,857173,233217,380246,631239,510228,649221,196239,809197,100152,479110,772132,693185,18397,317
9905 97,780413,070180,445252,780113,682221,857173,233217,380246,631239,510228,649221,196239,809197,100152,479110,772132,693185,18397,317
Appropriation of the result
9906 485,4393.4m3.1m2.9m2.7m2.6m2.3m2.2m2.0m1.7m1.5m1.2m1.0m775,545578,445425,966315,194282,50097,317
14P 387,6593.0m2.9m2.6m---------------
791/2 -216,136-----------------
694/7 15,8483.3m23,31817,93017,72317,882-----------100,000-
694 -3.3m-----------------
695 -----------------100,000-
696 15,84825,41123,31817,93017,72317,882-------------
Social balance sheet
9087 8.79.28.87.96.876.876.96.976.77.27.46.38.56.75.25.2
Hours worked1013 14,73814,91614,00912,78512,02212,27512,28112,11512,08611,44512,46212,36611,59512,55212,75213,14511,0799,1939,139
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The accounts for 6 older financial years (2001-2006) were filed as documents without figures as data, scans for example.

The notes to these accounts have 18 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 29-09-2025.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-03-2025 abbreviated format 29-09-2025 2025-00533713 PDF
31-03-2024 abbreviated format 29-10-2024 2024-00530533 PDF
31-03-2023 abbreviated format 31-10-2023 2023-00500601 PDF
31-03-2022 abbreviated format 28-10-2022 2022-20483455 PDF
31-03-2021 abbreviated format 15-11-2021 2021-77300482 PDF
31-03-2020 abbreviated format 17-11-2020 2020-70900028 PDF
31-03-2019 abbreviated format 24-10-2019 2019-71500018 PDF
31-03-2018 abbreviated format 27-09-2018 2018-65900333 PDF
31-03-2017 abbreviated format 14-09-2017 2017-60900373 PDF
31-03-2016 abbreviated format 06-09-2016 2016-59000237 PDF
31-03-2015 abbreviated format 22-09-2015 2015-59400314 PDF
31-03-2014 abbreviated format 20-10-2014 2014-65100036 PDF
31-03-2013 abbreviated format 30-09-2013 2013-60800469 PDF
31-03-2012 abbreviated format 19-10-2012 2012-61200563 PDF
31-03-2011 abbreviated format 03-10-2011 2011-57000119 PDF
31-03-2010 abbreviated format 21-10-2010 2010-58500227 PDF
31-03-2009 abbreviated format 28-09-2009 2009-78000067 PDF
31-03-2008 abbreviated format 28-10-2008 2008-79600153 PDF
31-03-2007 abbreviated format 22-10-2007 2007-77700293 PDF
31-03-2006 abbreviated format 23-10-2006 2006-84100217 PDF
31-03-2005 abbreviated format 12-10-2005 2005-82100013 PDF
31-03-2004 abbreviated format 06-10-2004 2004-70400206 PDF
31-03-2003 abbreviated format 29-10-2003 2003-76701645 PDF
31-03-2002 abbreviated format 12-11-2002 2002-70600137 PDF
31-03-2001 abbreviated format 18-10-2001 2001-64800107 PDF

Subsidies and aid

Flemish government 2023 to 2024, 2 entries, €1,155 awarded, €1,155 paid

Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
€1,155
Year Entries AwardedPaid
2024 1 €600€600
2023 1 €555€555

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420232022202120202019201820172016201520142013201220112010200920082007
237,051352,219291,750405,302284,332307,244256,468324,650390,683381,052383,308359,517376,799352,340282,687270,026303,083327,457266,246
202,315515,985261,128336,240183,791241,878191,464234,702274,086276,072281,221267,645287,443241,650206,008193,725232,937285,244198,212
32,3594,9931.3m356,045916,06343,8146,4436155,08013,91221,14566032,04718,0351,8279,96116,60517,91571,441
-286,246274,241-132,955-44,36789,006-276,710184,61589,373-13,12523,902-51,01761,181-192,109-151,322122,031-64,664-107,334-74,691-
657,231626,1623.1m3.0m2.8m2.8m2.6m2.4m2.2m2.0m1.7m1.5m1.3m1.1m937,211787,940694,878590,562467,816
18.2%13.9%53.5%63.2%67.3%79.3%76.5%76.5%73.8%73.2%64.1%56.7%50.5%43.8%39.1%32.9%28.7%22.1%20.0%
1.981.634.744.644.764.784.254.263.873.852.862.392.141.931.851.691.631.511.46
1.211.104.144.134.164.233.753.703.353.342.492.111.871.711.611.441.371.251.18
4.486.190.870.580.490.260.310.310.360.370.560.760.981.281.562.042.483.524.00
17.5%86.6%5.4%7.9%3.9%7.8%6.5%8.8%10.9%11.9%12.9%14.3%18.2%18.2%17.2%15.1%21.4%37.9%24.2%
3.2%12.0%2.9%5.0%2.6%6.2%5.0%6.7%8.1%8.7%8.3%8.1%9.2%8.0%6.7%5.0%6.1%8.4%4.8%
4.462.266.5314.54---------------

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-03-202531-03-202431-03-202331-03-2022
Employees at the balance-sheet date12131215
full-time2322
part-time10101013
in full-time equivalents9.29.18.19
8.79.28.87.9
On a permanent contract12111112
Joined3437
Left4363

Source: social balance sheet in the 2022 to 2025 annual accounts

Securities and guarantees

on own assets and for others
Item31-03-202531-03-202431-03-202331-03-2022
Debts secured on the company's own assets€1.9m--€750,000
Mortgages, amount registered€24,785--€750,000
€2.1m---
Carrying value of the mortgaged assets€1.6m--€703,808
€185,920---
Mandates to pledge the business---€185,920

Source: notes to the 2022 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)

Investments

fixed assets acquired
Item31-03-202531-03-202431-03-202331-03-2022
Tangible fixed assets€32,359€4,993€1.3m€356,045
€104,535€102,915€80,682€83,460

Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)

Insights on EXTRA-PHARMA

The operating result for 2025 is 47% lower than in 2024 and the lowest since 2007.

Debt's share of the balance-sheet total falls from 86.1% to 81.8%. Equity is higher and debt is lower.

Board & ownership

Board

1 director, no change since 2024
Cavely BV
Director, permanent representative Carlijn VAN DEN EEDE
current term since 02-04-2024
listed in the 2025 annual accounts, filed on 29-09-2025
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 20-10-2020
Permanent representatives 1
Carlijn VAN DEN EEDE
Permanent representative, for Cavely
appointed by deed of 27-05-2024

Office holders in the KBO →

Mandates through the years

4 names, the dashed line is today
Cavely
Director
VERLUCO
Director (not named in the articles)
Véronique VAN ROEY
Director (not named in the articles)
VAN DEN EEDE Luc Roger Johan Theo
Manager
BoardEarliermandate already running before its first mention
Mandates as a list
  • Cavely
    • Director, since before 31-03-2024
  • VERLUCO
    • Director (not named in the articles), appointed by deed of 20-10-2020, until 01-04-2024
    • Manager, until 20-10-2020
  • Véronique VAN ROEY
    • Director (not named in the articles), appointed by deed of 20-10-2020, until 01-04-2024
    • Manager, until 20-10-2020
  • VAN DEN EEDE Luc Roger Johan Theo
    • Manager, until 20-10-2020

See the board, name and registered office on a given date →

Control

Parent
Cavely
Equity €301,713
Profit €226,713 in 2025
Checked score 92
100%
This company
EXTRA-PHARMA
Equity €559,094
Profit €97,780 in 2025

Further up the chainApolyne 100%

and 1 other shareholder

Capital

Contribution
€18,600
Source
2025 annual accounts

Owners through the years

as the annual accounts name them
Cavely
100%
VERLUCO
98%
98% until 2023
Owners as a list

Source: lists of holdings in the owners' accounts

Articles of association

deed of 20-10-2020 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Wednesday of August at 20:00

Shareholders

2 owners

Owners 2

Network & group

Group

Cavely has 1 direct subsidiary (accounts to 30-06-2025), the bar shows equity in euros
ParentCavely1 holding, 1 country accounts to 30-06-2025

Belgium 1 Equity Result

  • BE Extra Pharma €559,094 result €97,780

Source: list of holdings in the 30-06-2025 accounts of Cavely. Every holding stands with its own latest accounts.

At the same address

Antwerpsesteenweg 188, 2950 Kapellen · 1 other company
Cavely
registered office since 12-03-2024 · founded in 2024
 total assets €2.6m (2025)
1007.012.626

Connections & network

1 current director
Depth

The network lets you explore the ties of EXTRA-PHARMA.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

34 events since 1999
2025
Annual accounts 2025 filed PDFabbreviated format · 32 days before the deadline
2024
Annual accounts 2024 filed PDFabbreviated format · 2 days before the deadline
1 director appointed, 2 resignationsResignations: Véronique VAN ROEY and VERLUCO NV · Permanent representatives: Luc VAN DEN EEDE and Carlijn VAN DEN EEDE · Appointment: CAVELY BV · General meeting of 02-04-20246 points ▸
  • General meeting, 02-04-2024, mentioned twice in the deed
  • Director resignation, Véronique VAN ROEY
  • Director resignation, VERLUCO NV
  • Permanent representative, Luc VAN DEN EEDE
  • Director appointment, CAVELY BV
  • Permanent representative, Carlijn VAN DEN EEDE (vaste vertegenwoordiger belast met uitvoering van voormeld mandaat in naam en voor rekening van de vennootschap)

Open the deed in the Belgian Official Gazette

Highest result from 2007 to 2025 net €413,070 ▲129% The net result of €413,070 is the highest of those years.
2023
Annual accounts 2023 filed PDFabbreviated format · on the deadline day
2022
Annual accounts 2022 filed PDFabbreviated format · 3 days before the deadline
Environmental permit granted OmgevingsloketNieuwbouw of aanleggen, Nieuwbouw van bijgebouwen, niet-overdekte lage constructies en andere handelingen, Verbouwen en/of uitbreiden met het wijzigen van alle zelfstandige gebruikseenheden (unit) binnen het gebouw and 2 more · Kapellen
2021
Annual accounts 2021 filed PDFabbreviated format · 15 days late
2020
Annual accounts 2020 filed PDFabbreviated format · 17 days late
1 manager resigningChanges of role: VAN ROEY Véronique (director) and VERLUCO (director) · Resignation: VAN DEN EEDE Luc Roger Johan Theo (manager) · “Het verlenen van advies en prestaties aan apotheken,verenigingen,bedrijven,de overheid,universiteiten en…” (deed in Dutch)10 points ▸

Open the deed in the Belgian Official Gazette

2019
Annual accounts 2019 filed PDFabbreviated format · 7 days before the deadline
2018
Annual accounts 2018 filed PDFabbreviated format · 34 days before the deadline
2017
Annual accounts 2017 filed PDFabbreviated format · 47 days before the deadline
2016
Annual accounts 2016 filed PDFabbreviated format · 55 days before the deadline
Equity above €2m equity €2.0m ▲13.5% With a profit in every financial year since 2007, equity grows to €2.0m.
2015
Annual accounts 2015 filed PDFabbreviated format · 39 days before the deadline
2014
Annual accounts 2014 filed PDFabbreviated format · 11 days before the deadline
2013
Annual accounts 2013 filed PDFabbreviated format · 31 days before the deadline
2012
Annual accounts 2012 filed PDFabbreviated format · 12 days before the deadline
Equity above €1m equity €1.1m ▲22.3% With a profit in every financial year since 2007, equity grows to €1.1m.
2011
Annual accounts 2011 filed PDFabbreviated format · 28 days before the deadline
2010
Annual accounts 2010 filed PDFabbreviated format · 10 days before the deadline
2009
Annual accounts 2009 filed PDFabbreviated format · 33 days before the deadline
Equity above €500,000 equity €620,832 ▲27.2% With a profit in every financial year since 2007, equity grows to €620,832.
2008
Annual accounts 2008 filed PDFabbreviated format · 3 days before the deadline
2007
Annual accounts 2007 filed PDFabbreviated format · 9 days before the deadline
2006
Annual accounts 2006 filed PDFabbreviated format · 8 days before the deadline
2005
Annual accounts 2005 filed PDFabbreviated format
2004
Annual accounts 2004 filed PDFabbreviated format
2003
Annual accounts 2003 filed PDFabbreviated format
2002
Annual accounts 2002 filed PDFabbreviated format
2001
Annual accounts 2001 filed PDFabbreviated format
2000
First establishment Antwerpsesteenweg 188, Kapellen
1999
Incorporation published on 06-11-1999

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

EXTRA-PHARMA was incorporated on 26 October 1999.1 Since 2024, Cavely has served as director.2 Total assets fell from €3.5m in 2019 to €3.1m in 2025 and headcount from 6.8 to 8.7 full-time equivalents.3

  1. 1KBO register
  2. 2National Bank, annual accounts 2025
  3. 3National Bank, annual accounts 2019 and 2025

Company details

Identity

Enterprise number
0467.149.426
VAT number
BE 0467.149.426
Peppol ID
0208:0467149426
Other Peppol ID
9925:BE0467149426
Legal form
Private limited company
Status
Active, normal situation
Founded
26-10-1999
Financial year
ends on 31 March
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Wednesday of August at 20:00
deed of 20-10-2020 (in Dutch)
Peppol
Reachable via PeppolFollow this company and you will hear the next morning if it leaves the Peppol register.
Name
EXTRA-PHARMA in Dutch
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 20-10-2020 (in Dutch)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest”
deed of 20-10-2020 (in Dutch)

Activities

NACEBEL 2025
VAT activities
47730 Retail sale of pharmaceutical products main activity
Social security (RSZ) activities
47730 Retail sale of pharmaceutical products main activity
Joint committees annual accounts 31-03-2025
JC 313 Pharmacies and pricing offices
Codes under NACEBEL 2008
VAT activities
47730 Retail trade main activity
Social security (RSZ) activities
47730 Retail trade main activity
Codes under NACEBEL 2003
VAT activities
52310 main activity
Social security (RSZ) activities
52310 main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“Het verlenen van advies en prestaties aan apotheken,verenigingen,bedrijven,de overhejd,universiteiten en verwante organisaties of…”
14 activities
  1. Het verlenen van advies en prestaties aan apotheken,verenigingen,bedrijven,de overhejd,universiteiten en verwante organisaties of instellingen
  2. Het nemen van participaties in andere ondernemingen
  3. Verlenen van advies en bijstand op het gebied van bedrijfsvoering en -beheer
  4. Het uitbaten van concessies,licenties en andere immateriële rechten en activa
  5. Het waarnemen van de mandaten van zaakvoerder,bestuurder en vereffenaar in andere vennootschappen
  6. Verstrekken van managementadviezen
  7. Organisatie van trainingen inzake voormelde activiteiten
  8. Alle roerende en onroerende goederen kopen,verkopen,huren,verhuren,bouwen,verbouwen,herstellen of ruilen,zonder dat dit een handel in onroerende goederen zou uitmaken
  9. Haar onroerende goederen in hypotheek stellen en al haar andere goederen,in pand stellen en aval verlenen voor alle leningen,kredietopeningen,en andere verbintenissen zowel voor haarzelf als voor derden
  10. Verstrekken van leningen en financieringen aan ondernemingen
  11. Aangaan van leningen
  12. Verstrekken van waarborgen
  13. Het verwerven en beheren van handelszaken
  14. Deelnemen of samenwerken met bestaande of nog op te richten ondernemingen die een gelijkaardig of complementair voorwerp hebben
deed of 20-10-2020 (in Dutch)

Registered office and establishments

1 establishment
Establishment Since Unit number
Antwerpsesteenweg 188 registered office 2950 Kapellen 10-07-2000 2.097.435.354

Buildings and parcels at the address

Ground area
1,164 m²
Buildings
317 m²
Volume, LiDAR
1,726 m³
Tallest building
11.6 m
Buildings to scale, each on its own parcel
317 m², 11.6 m 317 m², 11.6 m

Environmental permits

1 application in Flanders since 2021 · 1 granted
11-04-2022 Granted Nieuwbouw of aanleggen; Nieuwbouw van bijgebouwen, niet-overdekte lage constructies en andere handelingen; Verbouwen en/of uitbreiden met het wijzigen van alle zelfstandige gebruikseenheden (unit) binnen het gebouw; Verwijderen van vrijstaande bijgebouwen, niet-overdekte lage constructies of andere beperkte handelingen; Wijzigen van een publiciteitsinrichting submitted 25-12-2021 · project 2021179823 Kapellen

Source: Omgevingsloket Vlaanderen.

Location

registered office establishment The establishment unit on the map
2 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
11362N0339/02W0001,164 m² 1 · 317 m² 11.6 m · 1

We would like to set cookies. That happens only with your consent. What we measure